Phase 3
Completed N=152
Use Of Fragmin In Hemodialysis
Chronic Renal Failure
Source: ClinicalTrials.gov NCT01879618 ↗
Enrolled (actual)
152
Serious AEs
2.0%
Results posted
Dec 2016
Primary outcomePrimary: Mean Percent of Successful HD Sessions — 99.9 Percentage of HD Sessions
◆ Published Evidence
Emerging
5citations · ~1 / year
An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).
Summary
The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.
Linked Publications
-
An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Percent of Successful HD Sessions |
99.9 | — |
| SECONDARY Mean Percent of HD Sessions With an Acceptable Dose |
89.8 | — |
Eligibility Criteria
Inclusion Criteria
- chronic renal failure on hemodialysis
Exclusion Criteria
- significant comorbidities that would prevent a patient from completing the trial
Data sourced from ClinicalTrials.gov (NCT01879618) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.